Table 3.

Association between HtTKV at ESKD and clinical characteristics in male patients(univariate and multivariate analysis)

Predictor	n	Estimatea	95% CI	% change HtTKVb	P value
A - Univariate analysis- Male patients
Age at ESKD (per decade)	138	−0.031	−0.062 to 0.001	−6.9	0.06
Genotype
PKD1T-PKD1NT1	55	REF	REF	REF	REF
PKD1NT2-PKD2	25	−0.131	−0.242 to −0.019	−26.0	0.02
Body mass index (per 5 kg/m2)	134	0.025	−0.014 to 0.064	5.9	0.21
History of Smoking	138	0.040	−0.038 to 0.119	9.6	0.31
History of dyslipidemia	138	−0.060	0.139 to 0.018	−12.9	0.13
LDL (per 5 mg/dl)	50	−0.008	−0.018 to 0.001	−1.8	0.08
HDL (per 5 mg/dl)	47	−0.010	−0.034 to 0.013	−2.3	0.37
Framingham score (per 5%)	92	−0.017	−0.037 to 0.002	−3.8	0.07
High-risk score (≥20%)c	92	−0.113	−0.210 to −0.016	−22.9	0.02
Macrovascular disease	138	0.013	−0.077 to 0.103	3.0	0.77
B- Multivariate analysis- Male patients
Age at ESKD (decades)	50	−0.061	−0.250 to 0.128	−13.1	0.52
Genotype	50
PKD1T-PKD1NT1	-	REF	REF	REF	REF
PKD1NT2-PKD2	-	0.012	−0.208 to 0.231	2.8	0.92
LDL (per 5 mg/dl)	50	−0.001	−0.018 to 0.015	−0.2	0.87
Framingham Score (per 5%)	50	−0.015	−0.067 to 0.098	3.5	0.72
High-risk Framingham scorec	50	−0.110	−0.496 to 0.277	−22.4	0.58

CI, confidence interval; ESKD, end-stage kidney disease; HDL, high-density lipoprotein; HtTKV, total kidney volume adjusted for height; LDL, low-density lipoprotein.

^aBeta coefficient estimates derived from univariate linear or multivariate regression models using the log base 10 transformation on the outcome (HtTKV).

^bPercent change in HtTKV per unit increase in predictor variable was calculated by subtracting 1 from the log of the estimate then multiplying by 100: % change/unit increase in predictor = (10^{Beta Estimate} −1) ×100.

^cHigh-risk score is defined as having a Framingham score of ≥20%.